- Natera Inc NTRA posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product revenues.
- Product revenues rose 62% to $150.7 million. Licensing and other revenues rose 53% to $7.5 million.
- Natera processed approximately 407,300 tests in Q3, a 55% increase from Q3 2020.
- The firm's Q3 EPS loss widened to $(1.63) from $(0.72) a year ago and missing the consensus of $(1.27).
- The company ended the quarter with $95.1 million in cash and cash equivalents and $928.6 million in short-term investments.
- Guidance: Natera raised its FY21 revenue forecast to $615 million - $625 million, up from its previous forecast of $600 million - $620 million for the year. Analysts, on average, expect revenues of $614.7 million for 2021.
- Price Action: NTRA shares closed up 4.92% at $116.12 on Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in